Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sunesis Pharma (SNSS), Sarepta Therapeutics (SRPT) and Rewalk Robotics (RWLK).
Sunesis Pharma (SNSS)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Sunesis Pharma, with a price target of $1.50. The company’s shares closed on Friday at $0.90.
According to TipRanks.com, Fein is a 1-star analyst with an average return of -1.0% and a 38.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
Sunesis Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.75, which is a 316.7% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Sarepta Therapeutics (SRPT)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics today and set a price target of $267. The company’s shares closed on Friday at $119.57.
Chattopadhyay wrote:
“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.79, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.7%, and tax rate of 15% beginning in FY 2024.”
According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -1.5% and a 40.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $202.27, a 69.2% upside from current levels. In a report issued on June 5, Morgan Stanley also reiterated a Buy rating on the stock with a $165 price target.
Rewalk Robotics (RWLK)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright upgraded Rewalk Robotics to Buy, with a price target of $9. The company’s shares closed on Friday at $5.21, close to its 52-week low of $2.46.
Ramakanth noted:
“We upgrade our rating of RWLK to BUY from Neutral and adjust our 12-month price target to $9.00, up from $4.00. We derive our price target from an risk-adjusted net present value (rNPV) analysis of projected revenues from 2032 assuming a 9.1% discount rate and a 2% terminal growth rate. We derive an rNPV of $132M for the products and add in pro forma net cash of $17M to arrive at a 12-month price target of $8.95, which we round to $9.00.”
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.1% and a 30.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
Currently, the analyst consensus on Rewalk Robotics is a Hold with an average price target of $4.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
